Cabaletta Bio Inc

NASDAQ:CABA  
1.74
0.00 (0.00%)
7:37:56 PM EDT: $1.71 -0.03 (-1.71%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)156.50M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$4.17 Million
Adjusted EPS-$0.65
See more estimates
10-Day MA$1.67
50-Day MA$1.72
200-Day MA$2.46
See more pivots

Cabaletta Bio Inc Stock, NASDAQ:CABA

2929 Arch Street, Suite 600, Philadelphia, Pennsylvania 19104
United States of America
Phone: +1.267.759.3100
Number of Employees: 103

Description

Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.